List of Tables
Summary Table A: Global Proteomics Market, by End-User Industry, Through 2027
Summary Table B: Global Proteomics Market, by Platform, Through 2027
Table 1: Global Array Versus Lab-on-a-Chip (LOC) Biochips
Table 2: Scope of Report
Table 3: Global Proteomics Market, by Platform, Through 2027
Table 4: Global Biochips Market, by Type, Through 2027
Table 5: Driving Forces in the Growth of the Proteomics Industry
Table 6: Biochip Industry Comparisons
Table 7: Mass Spectrometry Generalized Workflow Schematic
Table 8: Mass Spectrometer Platforms
Table 9: Biochip-Based Proteomics Technologies
Table 10: Planar-Based Versus Bead-Based Arrays
Table 11: Advantages of Multiplexing for Diagnostics
Table 12: Technical Advances in Proteomics
Table 13: Proteomic Applications in Drug Discovery and Development
Table 14: Large-Scale Proteomics Initiatives
Table 15: Some Cancer Markers Used in Diagnosis and Treatment
Table 16: Strategies for Overcoming High-Abundance Proteins in Clinical Samples
Table 17: Status of Next-Generation Diagnostic Tests for Bladder Cancer
Table 18: Number of Annual Breast Cancer Treatment Decisions in the U.S, by Cancer Classification
Table 19: Breast Cancer MDx Technology Platforms
Table 20: Status of Next-Generation Tests for Breast Cancer
Table 21: Status of Next-Generation Diagnostic Tests for Gastric/Stomach Cancer
Table 22: Status of Next-Generation Diagnostic Tests for Kidney Cancer
Table 23: Status of Next-Generation Diagnostic Tests for Lung Cancer
Table 24: Status of Next-Generation Diagnostic Tests for Lymphomas
Table 25: Early Screening Tests for Ovarian Cancer
Table 26: Status of Next-Generation Diagnostics Tests for Ovarian Cancer
Table 27: Status of Next-Generation Diagnostics Tests for Pan-Cancer
Table 28: Status of Next-Generation Diagnostics Tests for Prostate Cancer
Table 29: Status of Next-Generation Diagnostics Tests for Thyroid Cancer
Table 30: Alzheimer's Disease Diagnostic Approaches
Table 31: Multiplex Autoimmune Testing Market
Table 32: Preeclampsia Diagnostic Tests
Table 33: Proteomics Industry Acquisitions, 2017-2022
Table 34: Strategic Alliances in the Proteomics Industry
Table 35: Mass Spectrometry Industry: Porter’s Five Forces Analysis
Table 36: First-Tier Mass Spectrometry Companies
Table 37: Second-Tier Mass Spectrometry Companies
Table 38: Leading Manufacturers of High-Performance Liquid Chromatography Columns
Table 39: Leading Manufacturers of High-Performance Liquid Chromatography Columns in Japan
Table 40: Proteomics-Based Drug Discovery Industry
Table 41: Key Peptide Microarray Companies
Table 42: Leading High-Density Protein Array Companies
Table 43: Key Antibody Microarray Companies
Table 44: Leading Companies in China's Biochip Industry
Table 45: Lab-on-a-Chip Competitor Landscape
Table 46: Antibody Reagent Market Share, by Company, 2021
Table 47: Multiplex Protein In Vitro Diagnostics Companies
Table 48: Dried Blood Spot Proteomics Industry
Table 49: Single Cell Proteomics Industry
Table 50: Factors Driving the Growth of the Proteomics Industry
Table 51: Global Proteomic Market, by End-User Industry, Through 2027
Table 52: Global Proteomics Research Market, by Platform, Through 2027
Table 53: Global Proteomics Research Market, by Biochip Platform, Through 2027
Table 54: Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
Table 55: Global Proteomics Biochip Drug Discovery and Development Market, by Biochip Platform, Through 2027
Table 56: Global Proteomics Diagnostic Market, by Platform, Through 2027
Table 57: Global Proteomics Diagnostic Market, by Biochip Type, Through 2027
Table 58: Global Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 59: Status of Proteomics-Based Diagnostics for Diabetes, Neurological, Autoimmune, Infectious Disease, HLA Typing, and Cardiovascular Disease Applications
Table 60: Sepsis Diagnostics Industry
Table 61: Global Proteomics Cancer Diagnostic Market, by Indication, Through 2027
Table 62: Global Mass Spectrometry Market, by Product Type, Through 2027
Table 63: Global Mass Spectrometry Market, by End-User Industry, Through 2027
Table 64: MRM-MS versus MALDI MS in Clinical Applications
Table 65: Status of MS Clinical Test Platforms
Table 66: Phosphoproteomics Platforms for Cancer Applications
Table 67: Global Proteomics Biochip Market, by Type, Through 2027
Table 68: Global Proteomics Arrays Market, by Type, Through 2027
Table 69: Global Proteomics Market, by End-User Industry, Through 2027
Table 70: Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
Table 71: Global Proteomics Lab-on-a-Chip Market, by End-User Industry, Through 2027
Table 72: Global Proteomics Market, by Region, Through 2027
Table 73: Global Proteomic Diagnostic Market, by Region, Through 2027
Table 74: North American Proteomics Market by Country, Through 2027
Table 75: North American Proteomics Market, by Platform, Through 2027
Table 76: North American Proteomics Market, by Biochips Platform, Through 2027
Table 77: North American Proteomics Market, by End User, Through 2027
Table 78: North American Drug Discovery and Development Market, by Platform, Through 2027
Table 79: North American Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 80: North American Proteomics Research Market, by Platform, Through 2027
Table 81: U.S. Proteomics Market, by Platform, Through 2027
Table 82: U.S. Proteomics Market, by Biochips Platform, Through 2027
Table 83: U.S. Proteomics Market, by End User, Through 2027
Table 84: U.S. Drug Discovery and Development Market, by Platform, Through 2027
Table 85: U.S. Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 86: U.S. Proteomics Research Market, by Platform, Through 2027
Table 87: Canadian Proteomics Market, by Platform, Through 2027
Table 88: Canadian Proteomics Market, by Biochips Platform, Through 2027
Table 89: Canadian Proteomics Market, by End User, Through 2027
Table 90: Canadian Drug Discovery and Development Market, by Platform, Through 2027
Table 91: Canadian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 92: Canadian Proteomics Research Market, by Platform, Through 2027
Table 93: European Proteomics Market, by Country, Through 2027
Table 94: European Proteomics Market, by Platform, Through 2027
Table 95: European Proteomics Market, by Biochips Platform, Through 2027
Table 96: European Proteomics Market, by End User, Through 2027
Table 97: European Drug Discovery and Development Market, by Platform, Through 2027
Table 98: European Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 99: European Proteomics Research Market, by Platform, Through 2027
Table 100: U.K. Proteomics Market, by Platform, Through 2027
Table 101: U.K. Proteomics Market, by Biochips Platform, Through 2027
Table 102: U.K. Proteomics Market, by End User, Through 2027
Table 103: U.K. Drug Discovery and Development Market, by Platform, Through 2027
Table 104: U.K. Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 105: U.K. Proteomics Research Market, by Platform, Through 2027
Table 106: German Proteomics Market, by Platform, Through 2027
Table 107: German Proteomics Market, by Biochips Platform, Through 2027
Table 108: German Proteomics Market, by End User, Through 2027
Table 109: German Drug Discovery and Development Market, by Platform, Through 2027
Table 110: German Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 111: German Proteomics Research Market, by Platform, Through 2027
Table 112: French Proteomics Market, by Platform, Through 2027
Table 113: French Proteomics Market, by Biochips Platform, Through 2027
Table 114: French Proteomics Market, by End User, Through 2027
Table 115: French Drug Discovery and Development Market, by Platform, Through 2027
Table 116: French Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 117: French Proteomics Research Market, by Platform, Through 2027
Table 118: Italian Proteomics Market, by Platform, Through 2027
Table 119: Italian Proteomics Market, by Biochips Platform, Through 2027
Table 120: Italian Proteomics Market, by End User, Through 2027
Table 121: Italian Drug Discovery and Development Market, by Platform, Through 2027
Table 122: Italian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 123: Italian Proteomics Research Market, by Platform, Through 2027
Table 124: Spanish Proteomics Market, by Platform, Through 2027
Table 125: Spanish Proteomics Market, by Biochips Platform, Through 2027
Table 126: Spanish Proteomics Market, by End User, Through 2027
Table 127: Spanish Drug Discovery and Development Market, by Platform, Through 2027
Table 128: Spanish Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 129: Spanish Proteomics Research Market, by Platform, Through 2027
Table 130: Rest of European Proteomics Market, by Platform, Through 2027
Table 131: Rest of European Proteomics Market, by Biochips Platform, Through 2027
Table 132: Rest of European Proteomics Market, by End User, Through 2027
Table 133: Rest of European Drug Discovery and Development Market, by Platform, Through 2027
Table 134: Rest of European Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 135: Rest of European Proteomics Research Market, by Platform, Through 2027
Table 136: Asia-Pacific Proteomics Market, by Country, Through 2027
Table 137: Asia-Pacific Proteomics Market, by Platform, Through 2027
Table 138: Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
Table 139: Asia-Pacific Proteomics Market, by End User, Through 2027
Table 140: Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
Table 141: Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 142: Asia-Pacific Proteomics Research Market, by Platform, Through 2027
Table 143: Chinese Proteomics Market, by Platform, Through 2027
Table 144: Chinese Proteomics Market, by Biochips Platform, Through 2027
Table 145: Chinese Proteomics Market, by End User, Through 2027
Table 146: Chinese Drug Discovery and Development Market, by Platform, Through 2027
Table 147: Chinese Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 148: Chinese Proteomics Research Market, by Platform, Through 2027
Table 149: Japanese Proteomics Market, by Platform, Through 2027
Table 150: Japanese Proteomics Market, by Biochips Platform, Through 2027
Table 151: Japanese Proteomics Market, by End User, Through 2027
Table 152: Japanese Drug Discovery and Development Market, by Platform, Through 2027
Table 153: Japanese Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 154: Japanese Proteomics Research Market, by Platform, Through 2027
Table 155: Indian Proteomics Market, by Platform, Through 2027
Table 156: Indian Proteomics Market, by Biochips Platform, Through 2027
Table 157: Indian Proteomics Market, by End User, Through 2027
Table 158: Indian Drug Discovery and Development Market, by Platform, Through 2027
Table 159: Indian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 160: Indian Proteomics Research Market, by Platform, Through 2027
Table 161: South Korean Proteomics Market, by Platform, Through 2027
Table 162: South Korean Proteomics Market, by Biochips Platform, Through 2027
Table 163: South Korean Proteomics Market, by End User, Through 2027
Table 164: South Korean Drug Discovery and Development Market, by Platform, Through 2027
Table 165: South Korean Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 166: South Korean Proteomics Research Market, by Platform, Through 2027
Table 167: Australian Proteomics Market, by Platform, Through 2027
Table 168: Australian Proteomics Market, by Biochips Platform, Through 2027
Table 169: Australian Proteomics Market, by End User, Through 2027
Table 170: Australian Drug Discovery and Development Market, by Platform, Through 2027
Table 171: Australian Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 172: Australian Proteomics Research Market, by Platform, Through 2027
Table 173: Rest of Asia-Pacific Proteomics Market, by Platform, Through 2027
Table 174: Rest of Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
Table 175: Rest of Asia-Pacific Proteomics Market, by End User, Through 2027
Table 176: Rest of Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
Table 177: Rest of Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 178: Rest of Asia-Pacific Proteomics Research Market, by Platform, Through 2027
Table 179: Rest of the World Proteomics Market, by Platform, Through 2027
Table 180: Rest of the World Proteomics Market, by Biochips Platform, Through 2027
Table 181: Rest of the World Proteomics Market, by End User, Through 2027
Table 182: Rest of the World Drug Discovery and Development Market, by Platform, Through 2027
Table 183: Rest of the World Proteomics Diagnostic Market, by Disease Type, Through 2027
Table 184: Rest of the World Proteomics Research Market, by Platform, Through 2027
Table 185: U.S. Proteomics Patents, 2017-2022
Table 186: Europe: Proteomics Patents, 2017-2022
Table 187: Japan: Proteomics Patents, 2017-2022
Table 188: Array-related Proteomics Patents, by Region, 2017-2022
Table 189: LOC-Related Proteomics Patents, by Region, 2017-2022
Table 190: Mass Spectrometry-Related Proteomics Patents, by Region, 2017-2022
Table 191: Major Mergers, Acquisitions, Collaborations, Partnership, Spin-Offs and Agreements
Table 192: FDA Clearances, Patents and Approvals, 2017-2022
Table 193: New Product Launches, 2017-2022
Table 194: Key Products of Sequencing and Next-Generation Sequencing Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 195: Top Manufacturers of PCR Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 196: Key Products of PCR Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 197: Top Manufacturers of Nucleic Acid Purification and Extraction Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 198: Key Products of Nucleic Acid Purification and Extraction Tools and Reagents and Their Manufacturers in Asia-Pacific
Table 199: Top Manufacturers of Nucleic Acid Separation Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
Table 200: Nucleic Acid Separation Technologies: Key Manufacturers’ Product Portfolio
Table 201: Agilent: Laboratory Automation Systems and Processes Portfolio
Table 202: Agilent Technologies Inc.: Developments
Table 203: BD: Laboratory Automation Systems and Processes Portfolio
Table 204: BioMerieux: FDA Bacteriology Products Approved in 2020
Table 205: BioMerieux: Key Developments, 2021
Table 206: Bio-Rad: Key Developments, 2021
Table 207: Danaher Corp.: Key Developments
Table 208: GE Healthcare: Product Portfolio
Table 209: General Electric: Financials, 2019
Table 210: GE Healthcare: Product Portfolio
Table 211: GE Healthcare: Recent Developments
Table 212: GlaxoSmithKline PLC: Product Segment
Table 213: GlaxoSmithKline PLC: Key Financials, 2021
Table 214: GlaxoSmithKline PLC: Vaccines Offered
Table 215: GlaxoSmithKline PLC: Flu Vaccines Sales
Table 216: GlaxoSmithKline PLC: Recent Developments
Table 217: Illumina Inc.: Revenues and R&D Expenditures
Table 218: Illumina Inc.: Key Developments
Table 219: PerkinElmer Inc.: Revenues and R&D Expenditures
Table 220: PerkinElmer Inc.: Laboratory Automation Systems and Processes Portfolio
Table 221: PerkinElmer Inc.: Selected Recent Developments
Table 222: Pressure BioSciences Inc.: Revenues and R&D Expenditures
Table 223: Pressure BioSciences Inc.: Key Developments
Table 224: Qiagen GmbH: Laboratory Automation Systems and Processes Portfolio
Table 225: Qiagen GmbH: Developments
Table 226: Roche: Business Segment
Table 227: Roche: Financials, 2021
Table 228: Roche: Financial Performance, 2018-2020
Table 229: Roche: Product Portfolio
Table 230: Roche: Diagnostics Patient Monitoring Product Portfolio
Table 231: Roche: Oncology Pharmaceutical Product Portfolio
Table 232: Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 233: Roche: Recent Developments
Table 234: Sanofi: Business Segment
Table 235: Sanofi: Financial Performance, 2021
Table 236: Sanofi-Aventis: Oncology Pharmaceuticals Product Portfolio
Table 237: Sanofi-Aventis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 238: Somalogic: Proteomics Methods
Table 239: Thermo Fisher Scientific Inc.: Product Portfolio
Table 240: Thermo Fisher Scientific Inc.: Developments
Table 241: Universal Biosensors Diagnostic Pipeline
Table 242: Waters Corp.: Revenues and R&D Expenditures
Table 243: Waters Corp.: Laboratory Automation Systems and Processes Portfolio
Table 244: Waters Corp.: Key Developments
List of Figures
Summary Figure A: Global Proteomics Market, by End-User Industry, 2019-2027
Summary Figure B: Global Proteomics Market, by Platform, 2022-2027
Figure 1: Proteomics Biochip and Array Formats
Figure 2: Chromatography Proteomics Workflow
Figure 3: Agilent: Annual Revenue, Life Sciences and Applied Markets Segment, 2019-2021
Figure 4: Agilent: Revenue Share, by Region, Life Sciences and Applied Markets Segment, 2021
Figure 5: Danaher Corp.: Revenue Share, by Segment, 2020
Figure 6: Danaher: Life Sciences Segment, Annual Revenue, 2019-2021
Figure 7: Danaher: Life Sciences Segment Revenue Share, by Region, 2021
Figure 8: General Electric Co.: Revenue Share, by Complementary Segment, 2020
Figure 9: General Electric Co.: Revenue Share, by Region/Country, 2020
Figure 10: GE Healthcare: Revenue Share, by Region, 2019
Figure 11: GE Healthcare: Revenue Share, by Segment, 2019
Figure 12: GlaxoSmithKline PLC: Net Revenue, 2016-2021
Figure 13: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
Figure 14: GlaxoSmithKline PLC: Revenue Share, by Region, 2021
Figure 15: Merck KGaA: Revenue Share, by Complementary Segment, 2020
Figure 16: Merck KGaA: Annual Revenue, 2017-2020
Figure 17: Merck KGaA: Revenue Share, by Region, 2020
Figure 18: Merck KGaA: Revenue Share, by Investment, 2020
Figure 19: Merck KGaA: Revenue Share, by Region, 2020
Figure 20: PerkinElmer Inc.: Annual Revenue, 2019-2021
Figure 21: PerkinElmer Inc.: Revenue Share, by Region, 2021
Figure 22: Qiagen: Annual Revenue, 2019-2021
Figure 23: Qiagen: Revenue Share, by Product Groups, 2021
Figure 24: Qiagen: Revenue Share, by Region, 2021
Figure 25: Roche: Revenue Share, by Segment, 2021
Figure 26: Roche: Total Sales Share, by Product Segment, 2020
Figure 27: Roche: Annual Revenue, 2019-2021
Figure 28: Roche Core Laboratory Diagnostics Segment: Annual Revenue, 2019-2021
Figure 29: Roche: Oncology Annual Revenue, 2018-2020
Figure 30: Sanofi: Net Sales Share, by Business Segment, 2021
Figure 31: Sanofi: Net Sales Share, by Region, 2021
Figure 32: Sanofi Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 33: Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2020
Figure 34: Thermo Fisher Scientific: Annual Revenue, 2019-2021
Figure 35: Thermo Fisher Scientific: Revenue Share, by Region, 2021
Figure 36: Waters Corp.: Annual Revenue, 2019-2021
Figure 37: Waters Corp.: Revenue Share, by Region, 2021
